证券代码：000423 证券简称：东阿阿胶 公告编号：2023-48 东阿阿胶股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1．会议时间：2023 年 08 月 29 日（星期二）15:30-17:00 4．问题征集：投资者可于 2023 年 8 月 28 日（星期一）12:00 前访问网址 https://eseb.cn/17nskq1FFV6 或使用微信扫描下方程序码，办理预约报名等手 续。在预约报名时可进行会前提问，公司将通过本次业绩说明会，在信息披露允 许范围内就投资者普遍关注的问题进行回答。 东阿阿胶股份有限公司（以下简称"公司"）已于 2023 年 8 月 26 日披露了 《2023 年半年度报告》。为便于广大投资者更加全面深入地了解公司发展战略及 经营业绩等情况，拟定于 2023 年 8 月 29 日举办 2023 年半年度业绩说明会。具 体内容如下： 一、召开时间、地点和方式 1．会议时间：2023 年 8 月 29 日（星期二）15:30-17:00 2．召开方式： ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2023-43 东阿阿胶股份有限公司 2023 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1．本次股东大会无否决议案。 2．本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）现场会议召开时间：2023 年 8 月 22 日上午 9 点 （七）会议出席情况：出席会议的股东（或股东代理人）共计123人， 303,396,886股，占上市公司总股份的47.1130％。其中： 通过现场投票的股东10人，代表股份212,720,499股，占上市公司总股份的 33.0323％。 通过网络投票的股东113人，代表股份90,676,387股，占上市公司总股份的 14.0807％。 （二）现场会议召开地点：公司会议室 （三）网络投票时间：通过深圳证券交易所交易系统投票的时间为2023年8 月22日上午9:15—9:25、9:30—11:30，下午13:00-15:00；通过深圳证券交易所 互联网投票系统投票的时间为2023年8月22日9:15-15 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥1,069,042,839.05, representing a 20.06% increase compared to ¥890,447,328.43 in the same period last year[3] - Net profit attributable to shareholders was ¥230,335,474.70, a significant increase of 100.86% from ¥114,675,694.25 year-on-year[3] - Basic earnings per share were ¥0.3577, reflecting a 100.84% increase compared to ¥0.1781 in the same period last year[3] - Total operating revenue for Q1 2023 reached ¥1,069,042,839.05, an increase of 20.1% compared to ¥890,447,328.43 in Q1 2022[16] - Net profit attributable to shareholders for Q1 2023 was ¥9,046,687,545.35, an increase from ¥8,816,352,070.66 in Q1 2022[15] - The total profit for the first quarter was CNY 278,794,220.63, compared to CNY 158,213,146.85 in the previous year, showing an increase of about 76.1%[17] Cash Flow and Liquidity - The net cash flow from operating activities reached ¥678,397,600.33, up 51.64% from ¥447,359,353.89 in the previous year[3] - The cash and cash equivalents balance at the end of the period was ¥5,992,481,744.13, a 66.33% increase from ¥3,602,742,355.22 year-on-year[7] - The cash flow from other operating activities was CNY 43,128,942.45, up from CNY 32,087,846.60, reflecting an increase of approximately 34.4%[19] - The company reported a decrease in investment cash flow, with a net cash outflow of CNY 26,269,224.53 compared to a net inflow of CNY 111,184,981.76 in the previous year[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥12,977,738,444.26, a 2.74% increase from ¥12,631,382,359.34 at the end of the previous year[3] - Total liabilities increased to ¥2,396,442,682.43 in Q1 2023, compared to ¥2,280,591,916.03 in Q1 2022[15] - The company's total current assets at the end of the reporting period amount to 10,181,564,387.63 RMB, an increase from 9,783,733,607.88 RMB at the beginning of the year[13] Shareholder Information - The total number of common shareholders at the end of the reporting period is 51,380[8] - The largest shareholder, China Resources Dong'e Ejiao Co., Ltd., holds 23.14% of the shares, totaling 151,351,731 shares[9] - The second largest shareholder, Hong Kong Central Clearing Limited, holds 8.93% of the shares, totaling 58,425,607 shares[9] - The total shares held by the top 10 shareholders account for 32.00% of the company's total equity[9] Expenses and Profitability - Total operating costs for Q1 2023 were ¥813,720,355.18, up 7.9% from ¥753,980,213.96 in the same period last year[16] - Research and development expenses for Q1 2023 were ¥22,050,936.58, down from ¥28,843,752.70 in Q1 2022, indicating a focus on cost management[16] - The company experienced a 33.78% increase in taxes and surcharges, driven by higher sales revenue[6] - The company reported a decrease in tax expenses, which were CNY 48,288,902.10 compared to CNY 43,500,813.18 in the previous year, indicating a rise in profitability despite higher revenues[17] Investment and Equity - Investment income decreased by 66.64%, from ¥13,043,620.40 to ¥4,351,746.21, due to differences in the maturity of financial products[6] - The company has a long-term equity investment of 85,500,686.14 RMB, down from 113,617,187.08 RMB at the beginning of the year[13] - The total equity attributable to shareholders reached ¥10,559,578,721.10, compared to ¥10,329,243,246.41 in the previous year[15] Other Financial Metrics - The weighted average return on equity was 2.21%, up from 1.15% year-on-year[3] - The company reported a significant increase in accounts payable, rising to ¥311,729,809.21 from ¥238,112,792.69 year-over-year[16] - The company incurred a credit impairment loss of CNY 6,261,066.73, compared to CNY 841,349.56 in the previous year, indicating an increase in credit risk[17] - The company's inventory at the end of the reporting period is 1,264,051,749.69 RMB, slightly increased from 1,238,592,184.11 RMB at the beginning of the year[13]

股票代码：000423 股票简称：东阿阿胶 东阿阿胶股份有限公司投资者关系活动记录表 编号：2023-02 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者 | □媒体采访 √业绩说明会 | | 关系活动类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | | 中信证券、国海证券、招商证券、东北证券、西部证券、中信建投、 申银万国、海通证券、中金公司、兴业证券、天风证券、国泰君安、 | | | 华西证券、西南证券、方正证券、安信证券、广发证券、中泰证券、 | | | 华创证券、华泰证券、东兴证券、东吴证券、申港证券、英大信托、 | | | 英大基金、嘉实基金、富国基金、慎知资产、汇添富基金、德邦资 | | | 管、湘财基金、递归基金、稳泰基金、东方证券资管、兴业基金、东 | | 参与单位名称 及人员姓名 | 方基金、睿远基金、奥博资本、大成基金、招商基金、广发基金、华 | | | 夏基金、建投基金、源峰基金、红筹投资、星石投资、神农投资、永 | | | 域资产、国信投资、建信基金、长盛基金、前海联合基金、阳光资 | | | 管、朋元资管、恒邦兆丰资管、凯丰 ...

Financial Performance - The company's operating revenue for 2022 was CNY 4,041,818,347.54, representing a 5.01% increase from CNY 3,848,985,686.56 in 2021[12]. - The net profit attributable to shareholders for 2022 was CNY 779,998,116.10, a significant increase of 77.10% compared to CNY 440,439,963.60 in 2021[12]. - The basic earnings per share for 2022 was CNY 1.21, up 77.94% from CNY 0.68 in 2021[12]. - The total assets at the end of 2022 amounted to CNY 12,631,382,359.34, an increase of 8.63% from CNY 11,628,031,898.88 at the end of 2021[12]. - The net profit after deducting non-recurring gains and losses for 2022 was CNY 699,829,938.05, an increase of 98.60% from CNY 352,383,752.92 in 2021[12]. - The company reported a net profit of CNY 267,099,762.61 in Q4 2022, with a net cash flow from operating activities of CNY 856,590,701.17[15]. - The company achieved a weighted average return on equity of 7.68% in 2022, up from 4.46% in 2021[12]. - The company reported a total of ¥4,640,000,000.00 in new purchases of trading financial assets during the reporting period, with a total of ¥5,240,000,000.00 sold[46]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2022, representing a year-over-year increase of 15%[124]. Cash Flow and Investments - The net cash flow from operating activities for 2022 was CNY 2,144,878,185.39, a decrease of 23.42% from CNY 2,800,902,528.25 in 2021[12]. - Cash and cash equivalents increased by 42.48% to ¥2,296,636,668.76[42]. - Investment activities generated a net cash flow of ¥589,507,998.15, a significant increase of 161.24% compared to the previous year[42]. - The company has a total of 30,000,000 CNY in principal guaranteed floating income products with an actual profit of 561.38 CNY[121]. - The company has entrusted 464,000 million RMB in bank wealth management products, with an unexpired balance of 185,000 million RMB[120]. Product Development and Market Strategy - The company has launched new products such as "Peach Blossom Princess" Ejiao cake and "Dong'e Ejiao" powder, targeting high-end female consumers and younger demographics[19][20]. - The company is focusing on expanding its market presence and product offerings in response to the growing demand for traditional Chinese medicine[18]. - The company is actively pursuing new product development and technological advancements to enhance its product offerings and market competitiveness[68]. - The company plans to enhance product differentiation and quality research, aiming to build competitive barriers and expand into multiple product categories[52]. - The company is considering strategic acquisitions to enhance its market position, with a budget of 500 million RMB allocated for potential deals[124]. Research and Development - The company is actively involved in research projects, including the clinical value assessment of Ejiao in treating cancer-related fatigue, which has shown significant improvement in patients' quality of life[21]. - The company has ongoing R&D projects aimed at developing traditional Chinese medicine products and health products, with significant clinical research backing[38]. - The company invested 200 million RMB in R&D for new technologies aimed at enhancing product efficacy and user experience[125]. - Research and development expenses decreased to ¥137,705,813.17 in 2022 from ¥147,749,402.42 in 2021, a decline of 6.9%[165]. Governance and Management - The company adheres to strict governance practices, ensuring compliance with relevant laws and regulations, and maintaining independence from its controlling shareholder[56][59]. - The company has established a reasonable mechanism for selecting its management team, ensuring clear responsibilities and accountability[58]. - The company has maintained a stable board of directors, with all current members serving until June 28, 2024[61]. - The company has conducted multiple investor communications, discussing overall business conditions, product positioning, and marketing strategies[55]. - The company reported a significant leadership change with the resignation of former Chairman and CEO Gao Dengfeng on February 20, 2023, due to work-related reasons[62]. Environmental and Social Responsibility - The company invested 5.26 million yuan in environmental governance and protection in 2022, with water resource tax expenditures amounting to 2.1529 million yuan[105]. - The company generated 3.731 million kWh of solar power in 2022, accounting for 16.07% of the total electricity consumption in the industrial park, resulting in a reduction of 3,720 tons of CO2 emissions[105]. - The company has a 100% monitoring rate, compliance rate, and disclosure rate for wastewater, waste gas, and noise monitoring[105]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[107]. Shareholder Information - The total number of shares held by Liu Guangli, a supervisor, increased by 900 shares during the reporting period[62]. - The total number of shares outstanding remained at 654,021,537, with no changes in shareholder structure[133]. - The largest shareholder, China Resources Dong'e Ejiao Co., Ltd., holds 151,351,731 shares, accounting for 23.14% of the total share capital[137]. - The company distributed dividends totaling ¥196,206,407.94 to shareholders during the year[175]. Financial Reporting and Compliance - The audit opinion issued by Ernst & Young was a standard unqualified opinion, confirming that the financial statements fairly reflect the company's financial position[146]. - The financial statements were approved by the board of directors on March 23, 2023, ensuring compliance with accounting standards[178]. - The company has maintained effective internal controls over revenue recognition and accounts receivable management[150]. - The company has not reported any penalties from regulatory authorities for its directors and supervisors in the last three years[73].

证券代码：000423 证券简称：东阿阿胶 公告编号：2023-17 东阿阿胶股份有限公司 关于召开 2022 年年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1．会议时间：2023 年 03 月 27 日（星期一）16:00-17:30 4．问题征集：投资者可于 2023 年 3 月 26 日（星期日）12:00 前访问网址 https://eseb.cn/13hoe1OKPO8 或使用微信扫描下方程序码，办理预约报名等手 续。在预约报名时可进行会前提问，公司将通过本次业绩说明会，在信息披露允 许范围内就投资者普遍关注的问题进行回答。 东阿阿胶股份有限公司（以下简称"公司"）已于 2023 年 3 月 25 日披露了 《2022 年年度报告》。为便于广大投资者更加全面深入地了解公司经营业绩、发 展战略等情况，拟定于 2023 年 3 月 27 日举办 2022 年年度业绩说明会。具体内 容如下： 一、召开时间、地点和方式 3．召开方式：现场互动 二、出席人员 董事、总裁 程杰先生，董事、董事会秘书、副总裁、财务总监 邓 ...

Group 1: Product Development and Market Strategy - The company has launched a new category of oral beauty products with a price of 1,099 RMB per 30 grams, targeting the high-end market through premium retail channels [2] - The company is conducting pilot tests in Guangzhou and Shanghai to assess consumer acceptance and product stability in high-temperature and high-humidity environments [2] - The company is building two networks: a downstream marketing network and an upstream raw material network, with the latter being a long-term project due to the current shortage of donkey hide resources [3] Group 2: Pricing Strategy and Market Position - The retail price of donkey-hide gelatin has increased from 400 RMB to around 800 RMB per pound, indicating a shift towards a higher-end consumer demographic with greater brand loyalty [3] - The company has been conducting detailed planning and measurement for price adjustments over the past eight years, considering factors such as raw materials, industry trends, and consumer acceptance [3] - The company is confident in its market expectations, product strength, brand power, and service quality [3] Group 3: Regulatory Environment and Quality Standards - The company anticipates that the future modification of national quality standards will favor high-quality enterprises, enhancing their competitive edge [4] - The trend towards stricter standards in advanced economies, as seen in the U.S. during the 60s and 70s, is expected to influence China's regulatory environment positively [4] - Improvements in production processes and product quality standards will increase consumer trust in the company's products [4]

Group 1: Raw Material Challenges - The traditional Chinese medicine industry faces a bottleneck in raw materials, particularly in donkey farming, which is declining due to mechanization [2] - The company aims to establish a comprehensive raw material base as part of its 12th Five-Year Plan, focusing on improving efficiency in donkey farming [2] Group 2: Marketing Strategies - The company is enhancing cultural marketing and value return for its products, with a 53% price increase for the compound donkey-hide gelatin (Ejiao) approved by the pricing bureau [2] - The new packaging of Ejiao, offering 48 pieces per box, aims to demonstrate significant effects and is a breakthrough innovation [2] - Research investment in Ejiao has reached millions, focusing on clinical studies for various health benefits [2] Group 3: Product Development - The company is developing new products like "Peach Blossom Princess" and small molecule Ejiao, with plans for market testing in Guangzhou [3] - The company is collaborating with universities for research on the safety and efficacy of its products, including evaluations of Ejiao's effects on various health conditions [5] Group 4: Competitive Landscape - The company acknowledges increasing competition in the Ejiao market and plans to focus on leading the industry by expanding its product range [5] - The company is committed to maintaining its market position by supporting upstream suppliers and ensuring profitability for donkey farmers [5] Group 5: Government Support and Market Trends - The total number of donkeys has been declining at a rate of 3% annually, but local areas are seeing some recovery [6] - Government subsidies for donkey farming vary by region, with specific financial support for breeding programs [6] Group 6: Product Classification and Efficacy - Ejiao is classified as a medicine with proven pharmacological effects, primarily promoting hematopoietic stem cell activity [7] - The company is actively researching and validating the health benefits of Ejiao through collaborations with various institutions [7]

Group 1: Direct Sales Business Progress - The company is preparing a team and designing a direct sales plan for its direct sales business [1] - The development of direct sales will positively impact the expansion of product sales channels and scope [3] Group 2: Raw Material Resources - The overall trend of donkey resources is declining due to agricultural mechanization and urbanization [3] - Local government has introduced supportive policies to promote the donkey industry [3] - The company has innovated a new model for the circular development and utilization of live donkeys to enhance their economic value [3] - The company is increasing efforts to develop foreign raw material resources while leveraging existing import countries [3] Group 3: Product Sales Situation - **Ejiao**: Limited overall production due to raw material constraints; revenue is steadily increasing as the consumer base expands to new and high-end groups [3] - **Compound Ejiao Syrup**: Comprehensive analysis and evaluation were conducted in 2014, leading to repositioning in price, specifications, and channels to enhance market competitiveness [4] - **Peach Blossom Ejiao Cake**: Adjustments in price and specifications were made in response to rising raw material costs; marketing will focus on key markets in Shandong and Beijing, with plans for national expansion [4]

Group 1: Company Development and Product Strategy - The company has a dual focus on domestic and international raw material sourcing, enhancing the value of donkey hides through live-cycle development [2] - Small molecule Ejiao has shown good market potential through trial sales in direct stores and e-commerce [2] - The company has become the top health supplement brand on Taobao and plans to expand its e-commerce business further [2] Group 2: Research and Development - Collaborations with Japan's pharmaceutical university and Chinese Academy of Sciences are underway to validate Ejiao's efficacy in skin hydration and anti-smog effects [3] - Research on Ejiao's benefits for pregnant women and fertility has been initiated with international research centers [3] - Over 3,000 cancer anemia samples have been studied, showing that Ejiao can help prevent neutropenia during chemotherapy [3] Group 3: Internet Strategy and Marketing - The company ranks highly in online sales of mid-to-high-end health products and has established a dedicated e-commerce division [4] - Targeted marketing strategies focus on high-end consumers, utilizing traditional cultural values to engage younger demographics [4] - Small molecule Ejiao will undergo testing in Guangzhou, targeting young professional women in major cities [4] Group 4: Quality Control and Supply Chain Management - The company has established 20 demonstration bases for donkey breeding to ensure raw material quality and traceability [5] - Strict internal quality control standards exceed national requirements, and the company participates in drafting national quality standards for Ejiao [5] - The company is transitioning from a health product provider to a health service provider, enhancing consumer access to product quality information [5] Group 5: Cultural Value and Consumer Engagement - The company aims to create a health management chain that educates consumers about Ejiao's cultural significance and benefits [6]